Journal article
Teratogenicity of the newer antiepileptic drugs - The Australian experience
FJE Vajda, J Graham, A Roten, CM Lander, TJ O'Brien, M Eadie
Journal of Clinical Neuroscience | Published : 2012
Abstract
Data on the use in pregnancy of the new antiepileptic drugs (AED) are limited. We analysed data collected by the Australian Pregnancy Register to provide information on their relative teratogenicity. The database containing pregnancy outcomes from 1317 women with epilepsy (WWE) was examined for three widely used new AED in monotherapy in the first trimester - lamotrigine, levetiracetam and topiramate. This was compared with outcomes of pregnant WWE on monotherapy with three traditional AED, and with untreated women. The incidence of malformations associated with lamotrigine monotherapy was 12/231 (5.2%), with topiramate 1/31 (3.2%) and with levetiracetam 0/22 (0%). This compares with rates o..
View full abstractGrants
Funding Acknowledgements
We thank our colleagues, the Advisory Board, the Ethics Committees, participating women, and our sponsors: the Epilepsy Society of Australia, Sanofi, UCB Pharma, Janssen, Pfizer, Novartis, National Health and Medical Research Council for a linkage grant, and the Royal Melbourne Hospital Neuroscience Foundation.